ArticleHealth affairs (Project Hope)2015
Growth In Buprenorphine Waivers For Physicians Increased Potential Access To Opioid Agonist Treatment, 2002-11.
Article in Health affairs (Project Hope), 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 101 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
101 citing papers in PubMed, 2 syntheses or guidelines pooled it, 158 citations in OpenAlex.
- Nurse prescribing right: a bibliometric analysis.Frontiers in medicine · 2025Pooled it
- Routes of non-traditional entry into buprenorphine treatment programs.Substance abuse treatment, prevention, and policy · 2020Pooled it
- Prescribers' satisfaction with delivering medications for opioid use disorder.Substance abuse treatment, prevention, and policy · 2021Trial
- Physicians' satisfaction with providing buprenorphine treatment.Addiction science & clinical practice · 2019Trial
- The Behavioral Health Treatment Engagement and Retention Learning Collaborative to Improve Receipt and Continuity of Medication Treatment for Opioid Use Disorder.Substance use & addiction journal · 2026Article
- Structural and Policy Determinants of Access to Medications for Opioid Use Disorder Among Pregnant People in U.S. Jails.International journal of environmental research and public health · 2026Article
- The Implementation Climate for Integrating Buprenorphine Prescribing into Rural Primary Care.Journal of general internal medicine · 2025Article
- Buprenorphine Treatment in Pregnancy and Maternal-Infant Outcomes.JAMA health forum · 2025Article
- Growing importance of high-volume buprenorphine prescribers in OUD treatment: 2009-2018.Drug and alcohol dependence · 2024Observational
- Rural-urban disparities in the availability of hospital-based screening, medications for opioid use disorder, and addiction consult services.Journal of substance use and addiction treatment · 2024Article
- County-level factors associated with a mismatch between opioid overdose mortality and availability of opioid treatment facilities.PloS one · 2024Article
- Utilization of Medications for Opioid Use Disorder Among West Virginia Medicaid Enrollees Following Medicaid Coverage of Methadone.Substance use & addiction journal · 2024Article
- Shifting drug markets in North America - a global crisis in the making?International journal of mental health systems · 2023Article
- Research Priorities for Expansion of Opioid Use Disorder Treatment in the Community Pharmacy.Substance abuse · 2023Article
- Trends in Geographic Proximity to Substance Use Disorder Treatment.American journal of preventive medicine · 2023Article
- Exploring the Association of State Policies and the Trajectories of Buprenorphine Prescriber Patient Caseloads.Substance abuse · 2023Article
- Association of Selected State Policies and Requirements for Buprenorphine Treatment With Per Capita Months of Treatment.JAMA health forum · 2023Article
- Multidimensional assessment of access to medications for opioid use disorder across urban and rural communities: A scoping review.The International journal on drug policy · 2023Article
- State Policies and Buprenorphine Prescribing by Nurse Practitioners and Physician Assistants.Medical care research and review : MCRR · 2022Article
- Racial/ethnic residential segregation and the availability of opioid and substance use treatment facilities in US counties, 2009-2019.SSM - population health · 2022Article
41 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
7 authors at 4 institutions in 2 countries.
Funding
Abstract
Opioid use disorders are a significant public health problem, affecting two million people in the United States. Treatment with buprenorphine, methadone, or both is predominantly offered in methadone clinics, yet many people do not receive the treatment they need. In 2002 the Food and Drug Administration approved buprenorphine for prescription by physicians who completed a course and received a waiver from the Drug Enforcement Administration, exempting them from requirements in the Controlled Substances Act. To determine the waiver program's impact on the availability of opioid agonist treatment, we analyzed data for the period 2002-11 to identify counties with opioid treatment shortages. We found that the percentage of counties with a shortage of waivered physicians fell sharply, from 98.9 percent in 2002 to 46.8 percent in 2011. As a result, the percentage of the US population residing in what we classified as opioid treatment shortage counties declined from 48.6 percent in 2002 to 10.4 percent in 2011. These findings suggest that the increase in waivered physicians has dramatically increased potential access to opioid agonist treatment. Policy makers should focus their efforts on further increasing the number and geographical distribution of physicians, particularly in more rural counties, where prescription opioid misuse is rapidly growing.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.